Progress of tolvaptan in treating heart failure

Tolvaptan is a novel oral selective arginine vasopressin V2-receptor antagonist. Tolvaptan improves heart failure signs and symptoms without serious adverse events. Tolvaptan has no effect on all-cause mortality and cardiovascular death or admission rate for heart failure. But in heart failure patients with hyponatremia, tolvaptan can decrease cardiovascular death and admission rate for heart failure. Key words: Tolvaptan; Heart failure, congestive; Hyponatremia